

Donna E Hansel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1370192/publications.pdf>

Version: 2024-02-01

81
papers

5,654
citations

126907

33
h-index

82547

72
g-index

85
all docs

85
docs citations

85
times ranked

7809
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. <i>World Journal of Urology</i> , 2022, 40, 915-927.	2.2	8
2	Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer. <i>Cancers</i> , 2022, 14, 758.	3.7	10
3	Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy. <i>Cancers</i> , 2022, 14, 1555.	3.7	18
4	Using Spike Gene Target Failure to Estimate Growth Rate of the Alpha and Omicron Variants of SARS-CoV-2. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0257321.	3.9	3
5	MRI appearance of BRCA-associated prostate cancer. <i>Clinical Imaging</i> , 2022, 84, 135-139.	1.5	2
6	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	2.5	143
7	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 295.e1-295.e8.	1.6	6
8	Establishment of Monoclonal Antibody Standards for Quantitative Serological Diagnosis of SARS-CoV-2 in Low-Incidence Settings. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab061.	0.9	8
9	Androgen Receptor Regulates CD44 Expression in Bladder Cancer. <i>Cancer Research</i> , 2021, 81, 2833-2846.	0.9	27
10	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	4.3	20
11	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	4.3	23
12	Expression of uroplakin II and GATA-3 in bladder cancer mimickers: caveats in the use of a limited panel to determine cell of origin in bladder lesions. <i>Human Pathology</i> , 2021, 113, 28-33.	2.0	4
13	Bladder Cancer Invasion Is Mediated by Mammalian Target of Rapamycin Complex 2-Driven Regulation of Nitric Oxide and Invadopodia Formation. <i>American Journal of Pathology</i> , 2021, 191, 2203-2218.	3.8	7
14	Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. <i>Nature Reviews Urology</i> , 2021, , .	3.8	6
15	Comparison of SARS-CoV-2 PCR-Based Detection Using Saliva or Nasopharyngeal Swab Specimens in Asymptomatic Populations. <i>Microbiology Spectrum</i> , 2021, 9, e0006221.	3.0	10
16	A 25 year perspective on advances in the pathologic assessment and diagnosis of urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 582-594.	1.6	4
17	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer- An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
18	Urothelial Proliferation of Unknown Malignant Potential Involving the Bladder: Histopathologic Features and Risk of Progression in De Novo Cases and Cases With Prior Neoplasia. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 853-862.	2.5	8

#	ARTICLE	IF	CITATIONS
19	Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 140.	7.4	36
20	Case Report: Chilblains-like lesions (COVID-19 toes) during the pandemic - is there a diagnostic window?. <i>F1000Research</i> , 2020, 9, 668.	1.6	4
21	Dynamic Regulation of Caveolin-1 Phosphorylation and Caveolae Formation by Mammalian Target of Rapamycin Complex 2 in Bladder Cancer Cells. <i>American Journal of Pathology</i> , 2019, 189, 1846-1862.	3.8	13
22	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. <i>Human Pathology</i> , 2019, 94, 58-63.	2.0	6
23	A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. <i>Human Pathology</i> , 2019, 88, 48-59.	2.0	2
24	SIUâ€™ICUD on bladder cancer: pathology. <i>World Journal of Urology</i> , 2019, 37, 41-50.	2.2	8
25	Nonâ€™urothelial carcinomas of the bladder. <i>Histopathology</i> , 2019, 74, 97-111.	2.9	29
26	Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20. <i>Endocrine Pathology</i> , 2018, 29, 236-241.	9.0	9
27	Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. <i>European Urology</i> , 2018, 73, 560-569.	1.9	401
28	Oxidized analogs of Di(1<i>H</i>-indol-3-yl)methyl-4-substituted benzenes are NR4A1-dependent UPR inducers with potent and safe anti-cancer activity. <i>Oncotarget</i> , 2018, 9, 25057-25074.	1.8	5
29	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î² Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7.	6.2	134
30	Can multiphase CT scan distinguish between papillary renal cell carcinoma type 1 and type 2?. <i>Turkish Journal of Urology</i> , 2018, 44, 316-322.	1.3	4
31	Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 593-599.	1.6	20
32	The Gleason Grading System: The Approach that Changed Prostate Cancer Assessment. <i>Journal of Urology</i> , 2017, 197, S140-S141.	0.4	0
33	Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinaseâ€™Mediated Eukaryotic Initiation Factor 2Î± Activity and Is Targetable byâ€™Pegylated Arginine Deiminase. <i>American Journal of Pathology</i> , 2017, 187, 200-213.	3.8	23
34	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	28.9	1,742
35	Metabolomics analysis reveals distinct profiles of nonmuscleâ€™invasive and muscleâ€™invasive bladder cancer. <i>Cancer Medicine</i> , 2017, 6, 2106-2120.	2.8	57
36	Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis. <i>Cancer Research</i> , 2017, 77, 4858-4867.	0.9	19

#	ARTICLE	IF	CITATIONS
37	Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?. <i>Urology</i> , 2017, 102, 7-16.	1.0	15
38	mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer. <i>Cellular Signalling</i> , 2017, 29, 96-106.	3.6	11
39	Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 323-336.	3.4	42
40	Adrenal Pathology in the Adult: A Urological Pathologist's Perspective. <i>Advances in Anatomic Pathology</i> , 2016, 23, 273-284.	4.3	5
41	Transforming Growth Factor- β 2 Is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion. <i>American Journal of Pathology</i> , 2016, 186, 1351-1360.	3.8	33
42	A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. <i>Pathology</i> , 2016, 48, 543-549.	0.6	37
43	An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. <i>Cancer Cell</i> , 2016, 30, 432-443.	16.8	58
44	The Emerging Molecular Landscape of Urothelial Carcinoma. <i>Surgical Pathology Clinics</i> , 2016, 9, 391-404.	1.7	30
45	Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 543-551.	2.5	79
46	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , 2016, 69, 441-449.	2.9	82
47	Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 699-706.	7.7	14
48	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. <i>Nature</i> , 2015, 521, 94-98.	27.8	451
49	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 53-64.	1.6	11
50	Morphologic and Molecular Characteristics of Bladder Cancer. <i>Surgical Pathology Clinics</i> , 2015, 8, 663-676.	1.7	8
51	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , 2015, 28, 612-630.	5.5	106
52	Long-term Survival From Muscle-invasive Bladder Cancer With Initial Presentation of Symptomatic Cerebellar Lesion: The Role of Selective Surgical Extirpation of the Primary and Metastatic Lesion. <i>Reviews in Urology</i> , 2015, 17, 106-9.	0.9	2
53	Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1108-1115.	1.6	24
54	Role in Tumor Growth of a Glycogen Debranching Enzyme Lost in Glycogen Storage Disease. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	38

#	ARTICLE	IF	CITATIONS
55	Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. <i>Human Pathology</i> , 2014, 45, 1473-1482.	2.0	110
56	Micropapillary bladder cancer: Current treatment patterns and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 826-832.	1.6	48
57	Uroplakin <sc>II</sc> outperforms uroplakin <sc>III</sc> in diagnostically challenging settings. <i>Histopathology</i> , 2014, 65, 132-138.	2.9	43
58	Highlights from the first symposium on upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 309-316.	1.6	15
59	Gene profiling suggests a common evolution of bladder cancer subtypes. <i>BMC Medical Genomics</i> , 2013, 6, 42.	1.5	9
60	ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. <i>European Urology</i> , 2013, 63, 16-35.	1.9	107
61	A Contemporary Update on Pathology Standards for Bladder Cancer: Transurethral Resection and Radical Cystectomy Specimens. <i>European Urology</i> , 2013, 63, 321-332.	1.9	103
62	Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. <i>Human Pathology</i> , 2013, 44, 164-172.	2.0	79
63	The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells <i>In Vitro</i> and <i>In Vivo</i>. <i>Clinical Cancer Research</i> , 2013, 19, 1717-1728.	7.0	83
64	Mammalian Target of Rapamycin Complex 2 (mTORC2) Is a Critical Determinant of Bladder Cancer Invasion. <i>PLoS ONE</i> , 2013, 8, e81081.	2.5	35
65	Selective Immunohistochemical Markers to Distinguish Between Metastatic High-Grade Urothelial Carcinoma and Primary Poorly Differentiated Invasive Squamous Cell Carcinoma of the Lung. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1339-1346.	2.5	72
66	Clinicopathologic Characteristics of 23 Cases of Invasive Low-grade Papillary Urothelial Carcinoma. <i>Urology</i> , 2012, 80, 361-366.	1.0	13
67	Prognostic Value of Cell-Cycle Regulation Biomarkers in Bladder Cancer. <i>Seminars in Oncology</i> , 2012, 39, 524-533.	2.2	61
68	Limited smoothelin expression within the muscularis mucosae: validation in bladder diverticula. <i>Human Pathology</i> , 2011, 42, 1770-1776.	2.0	26
69	Neoadjuvant Systemic Therapy or Early Cystectomy? Single-center Analysis of Outcomes After Therapy for Patients With Clinically Localized Micropapillary Urothelial Carcinoma of the Bladder. <i>Urology</i> , 2011, 77, 867-870.	1.0	70
70	HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. <i>Modern Pathology</i> , 2011, 24, 1111-1119.	5.5	88
71	Interobserver Reproducibility in the Diagnosis of Invasive Micropapillary Carcinoma of the Urinary Tract Among Urologic Pathologists. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1367-1376.	3.7	111
72	Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. <i>BMC Medical Genomics</i> , 2010, 3, 58.	1.5	50

#	ARTICLE	IF	CITATIONS
73	Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma. <i>American Journal of Pathology</i> , 2010, 176, 3062-3072.	3.8	65
74	Histopathologic Features and Clinical Outcomes in 71 Cases of Bladder Diverticula. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 791-796.	2.5	62
75	Mesenchymal Tumors of the Prostate. <i>Surgical Pathology Clinics</i> , 2008, 1, 105-128.	1.7	3
76	Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 895-905.	2.4	7
77	Role of Cystitis Cystica et Glandularis and Intestinal Metaplasia in Development of Bladder Carcinoma. <i>Urology</i> , 2008, 71, 915-918.	1.0	91
78	Benign Diseases of the Bladder. <i>Surgical Pathology Clinics</i> , 2008, 1, 129-158.	1.7	4
79	<i>HER2</i> Overexpression and Amplification in Urothelial Carcinoma of the Bladder Is Associated With <i>MYC</i> Coamplification in a Subset of Cases. <i>American Journal of Clinical Pathology</i> , 2008, 130, 274-281.	0.7	66
80	Renal Carcinoid Tumor: A Clinicopathologic Study of 21 Cases. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1539-1544.	3.7	94
81	Squamous Cell Carcinoma of the Bladder: A Clinicopathologic Analysis of 45 Cases. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1777-1787.	3.7	126